CDK1 Specific Neutra™ Antibody Products

Struggling with prolonged drug development cycles or inconsistent cell cycle regulation data? Creative Biolabs' CDK1 specific Neutra™ antibody products leverage advanced hybridoma engineering and epitope-specific validation to accelerate oncology research and therapeutic antibody discovery.

Introduction to CDK1

Cyclin-dependent kinase 1 (CDK1), a serine/threonine kinase, serves as the central regulator of the eukaryotic cell cycle. It governs the G2/M phase transition, ensuring genomic integrity through precise coordination of mitotic entry and progression. CDK1 activity is tightly regulated by binding to cyclin B and phosphorylation events, making it indispensable for cellular proliferation and survival. Dysregulation of CDK1 is a hallmark of uncontrolled cell division, directly linking it to oncogenesis and therapeutic resistance.

• Basic Information

CDK1 is the only essential CDK for cell division in most eukaryotes. Its expression peaks during the G2/M phase, where it phosphorylates substrates critical for nuclear envelope breakdown, chromatin condensation, and spindle assembly. Unlike other CDKs, CDK1's functional redundancy is minimal, underscoring its non-redundant role in mitosis.

• Structural Insights

The kinase domain of CDK1 contains a canonical PSTAIRE helix critical for cyclin binding. Activation requires binding to cyclin B and phosphorylation at Thr161 by CDK-activating kinase (CAK). Conversely, inhibitory phosphorylation at Tyr15 and Thr14 by Wee1/Myt1 kinases ensures temporal control. Structural studies reveal that cyclin B binding induces conformational changes, exposing the active site for substrate recognition.

• Related Signaling Pathways

CDK1 integrates signals from DNA damage checkpoints, metabolic sensors, and mitotic regulators:

- Cell Cycle Control: CDK1-cyclin B phosphorylates Cdc25, creating a feedback loop to amplify mitotic entry.

- DNA Damage Response: Activated CDK1 overrides G2 arrest by suppressing p53-dependent pathways, promoting repair or apoptosis.

- Apoptosis Regulation: CDK1 phosphorylates anti-apoptotic proteins like Bcl-2, linking mitotic errors to programmed cell death.

Fig.1 Role of CDK1 in apoptosis induction.¹

• Pathological Relevance

CDK1 overexpression is prevalent in aggressive cancers, including triple-negative breast cancer, ovarian carcinoma, and glioblastoma. Its hyperactivity drives genomic instability, chemoresistance, and metastatic spread. Targeting CDK1 offers therapeutic potential to halt proliferation in tumors with dysregulated cell cycle checkpoints.

Applications of CDK1 Neutralizing Antibodies

• Cell Cycle Analysis in Cancer Research

Anti-CDK1 antibodies enable precise tracking of mitotic progression in live-cell imaging and flow cytometry. By inhibiting CDK1 activity, researchers can model mitotic catastrophe in cancer cells, identifying vulnerabilities for targeted therapy.

• Therapeutic Development for Oncology

Neutralizing CDK1 disrupts tumor proliferation in preclinical models, particularly in cancers with intact G1/S checkpoints. These antibodies serve as benchmarks for validating small-molecule CDK1 inhibitors, streamlining lead compound optimization.

• Biomarker Validation in Clinical Trials

CDK1 expression levels correlate with poor prognosis in multiple malignancies. Our antibodies support biomarker discovery in patient-derived xenografts, aiding stratification for CDK1-targeted clinical trials.

• Drug Resistance Mechanism Elucidation

Persistent CDK1 activation underlies resistance to taxanes and PARP inhibitors. Neutralizing antibodies help delineate bypass signaling pathways, informing combinatorial therapy design.

Our Anti-CDK1 Neutralizing Antibodies

Creative Biolabs' CDK1 specific antibodies are rigorously validated for high specificity and functional efficacy. These antibodies recognize conformational epitopes within the kinase domain, effectively inhibiting CDK1-cyclin B complex formation and substrate phosphorylation. Key features include:

- Precision Detection: Enables quantification of CDK1 activation states in tumor biopsies via immunohistochemistry.

- Functional Neutralization: Blocks kinase activity in vitro, facilitating drug synergy studies and resistance mechanism exploration.

- Cross-Species Reactivity: Validated in human, mouse, and rat models for translational research consistency.

Creative Biolabs offers CDK1 specific Neutra™ antibodies, which are engineered to meet the highest standards of reproducibility and specificity.

Contact our scientific team today to discuss customized solutions for your CDK1-targeted projects.

REFERENCE

1. Wijnen, Rosa, et al. "Cyclin dependent kinase-1 (CDK-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC)." Cancers 13.17 (2021): 4389. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers13174389